AVEO Pharmaceuticals logo
AVEO Pharmaceuticals AVEO

Quarterly report 2022-Q3
added 11-07-2022

report update icon

AVEO Pharmaceuticals Financial Statements 2011-2025 | AVEO

Annual Financial Statements AVEO Pharmaceuticals

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

98 M 170 M 79.7 M 213 M 320 M 42.3 M 56.3 M 49.7 M 85 M 332 M 527 M

Shares

32.7 M 21.4 M 15.3 M 12.1 M 10.6 M 6.93 M 5.57 M 5.23 M 5.09 M 4.34 M 3.97 M

Historical Prices

3.54 8.26 4.4 5.4 28.6 8.4 9.8 12.5 18.7 66.7 130

Net Income

-53.3 M -35.6 M 9.39 M -5.33 M -65 M -26.9 M -15 M -52.7 M -107 M -114 M 30.6 M

Revenue

42.3 M 6.02 M 28.8 M 5.41 M 7.58 M 2.52 M 19 M 18.1 M 1.29 M 19.3 M 165 M

Cost of Revenue

4.74 M - - - - - - - - - -

Gross Profit

- 4.77 M - - - - - - - - 165 M

Operating Income

-49.6 M -38.9 M -374 K -25.4 M -28.8 M -29.4 M -12.4 M -50.4 M -104 M -112 M 33.9 M

Interest Expense

- 1.6 M 1.82 M 2.19 M 2.37 M 1.95 M 2.31 M 2.39 M 3.13 M 3.5 M 3.84 M

EBITDA

-49.5 M -38.9 M -374 K -23.7 M -26.7 M -29.4 M 1.5 M -32.5 M -92.1 M -106 M 35.6 M

Operating Expenses

- 44.9 M 29.2 M 31.4 M 34.3 M 31.9 M 27.1 M 56.8 M 97.2 M 128 M 131 M

General and Administrative Expenses

60.8 M 22.2 M 11.2 M 10.8 M 9.14 M 8.2 M 14.2 M 18.6 M 28.7 M 36.9 M 29.2 M

All numbers in USD currency

Quarterly Income Statement AVEO Pharmaceuticals

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- 34.6 M - 34.5 M 34.5 M 34.4 M 34.4 M 27.4 M 26.3 M 25.8 M 17.4 M 16.1 M 16.1 M 16.1 M 15.9 M 13.2 M 12.4 M 12 M 11.9 M 11.9 M 118 M 118 M 111 M 76.2 M 75.9 K 75.9 M 66.9 M 58.2 M 58.2 M 56.8 M 55.2 M 52.6 M 52.3 M 51.8 M 51.7 M 51.6 M 51.8 M 51.4 M 51.3 M 49.4 M 43.8 M 43.4 M 43.3 M 43.3 M 43.3 M 43 M 36.8 M 35.8 M

Net Income

- -3.27 M -8.32 M -10.2 M -7.26 M -10.4 M -13.6 M -22.1 M -11.5 M -8.39 M -7.31 M -8.38 M -4.46 M 16.4 M -3.14 M 555 K 21.8 M -22.2 M 4 M -8.99 M 3.5 M -26.4 M -33.3 M -8.84 M -5.6 M -4.97 M -8.61 M -7.71 M -6.58 M 7.91 M -5.46 M -10.9 M -13.9 M -14.4 M -18 M -6.45 M -16.7 M -24.3 M -31.9 M -34.1 M -21.5 M -30.1 M -29.5 M -33.2 M -25.2 M -23.8 M -5.73 M 85.4 M

Revenue

- 30.4 M - 20.9 M 17.6 M 15.2 M 7.56 M 1.92 M 886 K 20 M 20 M 20 M 764 K 25.7 M 703 K 1.61 M 1.48 M 2.47 M 433 K 1.03 M 82 K 4.61 M 351 K 2.53 M 127 K 992 K 193 K 1.2 M 3.6 M 15.2 M 134 K 134 K 115 K 873 K 1.85 M 15.3 M 323 K 323 K 324 K 323 K 15.5 M 1.02 M 1.88 M 860 K 1.1 M 3.58 M 26.6 M 134 M

Cost of Revenue

- 3.96 M - 2.43 M 2.03 M 1.74 M 822 K 138 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

- -2.17 M - -9.01 M -6.16 M -9.22 M -15.1 M -19.1 M -12.7 M -8.06 M -7.41 M -10.7 M -6.63 M 18.8 M -4.89 M -7.7 M -6.34 M -5.41 M -6.57 M -7.03 M -10.1 M -2.15 M -8.83 M -7.76 M -9.43 M -5.59 M -7.14 M -7.23 M -6.12 M 8.47 M -4.62 M -10.1 M -13 M -14.1 M -17.5 M -5.89 M -16.1 M -23.6 M -31.1 M -33.2 M -20.6 M -29.4 M -28.8 M -32.9 M -24.4 M -23.1 M -4.9 M 86.4 M

Interest Expense

- - - - - - 1.13 M 611 K - 419 K 349 K 315 K - 467 K 451 K 564 K - 579 K 549 K 493 K - 655 K 530 K 551 K - 551 K 468 K 369 K - 531 K 626 K 716 K - 439 K 502 K 581 K - 756 K 825 K 870 K -882 K 888 K 880 K 845 K -737 K 953 K 946 K 1.01 M

EBITDA

- -2.12 M - -8.99 M -6.16 M -9.16 M -15.1 M -19.1 M -12.7 M -8.05 M -7.4 M -10.7 M -6.63 M 18.8 M -4.89 M -7.7 M -6.34 M -5.41 M -6.57 M -7.03 M -10.1 M -2.15 M -8.83 M -7.76 M -9.43 M -5.59 M -7.14 M -7.23 M -6.12 M 18 M 4.84 M -5.66 M -13 M -11.3 M -15.8 M -5.05 M -16.1 M -20.8 M -29.2 M -32.3 M -20.6 M -27.6 M -27.6 M -32.4 M -24.4 M -21.9 M -4.13 M 86.7 M

Operating Expenses

- - - - - 24.4 M 22.6 M 21 M 13.6 M 11.7 M 8.16 M 11.5 M 7.4 M 6.87 M 5.6 M 9.31 M 7.83 M 7.88 M 7 M 8.06 M 10.2 M 6.77 M 9.18 M 10.3 M - 6.58 M 7.34 M 8.44 M - 6.69 M 4.76 M 10.3 M 11.8 M 15 M 19.3 M 21.2 M 16.4 M 23.9 M 31.4 M 33.5 M 36.1 M 30.4 M 30.6 M 33.8 M 25.5 M 26.7 M 31.4 M 47.2 M

General and Administrative Expenses

- 17.6 M - 17.3 M 15.7 M 15.1 M 14.9 M 15.1 M 9.01 M 5.8 M 3.74 M 3.67 M - 2.88 M 2.99 M 2.46 M - 2.72 M 2.83 M 2.61 M - 2.1 M 2.3 M 2.33 M - 2.14 M 1.73 M 2.46 M - 2.22 M 2.89 M 3.26 M - 5.08 M 4.85 M 5.56 M - 4.44 M 7.32 M 12.4 M - 9.3 M 9.19 M 8.98 M - 6.58 M 6.37 M 9.23 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements AVEO Pharmaceuticals AVEO
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting AVEO Pharmaceuticals plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.9 4.03 % $ 813 M canadaCanada
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 3.21 -1.38 % $ 248 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Aptevo Therapeutics Aptevo Therapeutics
APVO
$ 1.06 -6.22 % $ 293 K usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 13.33 -5.39 % $ 878 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 214.55 -2.66 % $ 5 B danmarkDanmark
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.1 -5.93 % $ 7.46 B australiaAustralia
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 27.09 -1.53 % $ 1.74 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 88.51 0.59 % $ 9.14 B usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
$ 24.35 3.07 % $ 2.88 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
CureVac N.V. CureVac N.V.
CVAC
$ 5.02 -0.59 % $ 934 M germanyGermany
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
BioVie BioVie
BIVI
$ 1.43 -1.72 % $ 2.11 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
BioNTech SE BioNTech SE
BNTX
$ 93.99 -0.86 % $ 27.2 B germanyGermany
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
$ 10.88 0.74 % $ 1.41 B usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 26.44 4.63 % $ 1.28 B usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 9.6 0.42 % $ 141 M usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
$ 15.97 -4.37 % $ 410 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 0.26 -6.9 % $ 566 M israelIsrael
Evogene Ltd. Evogene Ltd.
EVGN
$ 1.04 -3.7 % $ 27.9 M israelIsrael
Exelixis Exelixis
EXEL
$ 41.27 0.95 % $ 12 B usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Foghorn Therapeutics Foghorn Therapeutics
FHTX
$ 4.39 -1.13 % $ 241 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 551.37 -2.29 % $ 41.8 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
$ 2.35 2.17 % $ 14.8 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
$ 91.19 1.51 % $ 96.9 B britainBritain
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 8.88 -1.33 % $ 1.45 B britainBritain
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 11.25 -2.43 % $ 728 M usaUSA
Biogen Biogen
BIIB
$ 174.69 0.34 % $ 25.4 B usaUSA